Steven Lin, MD PhD
Closed to Accrual & Treatment
Lung [LU]
Non-small Cell Lung Cancer
I
No
To evaluate if the addition of MEDI4736 (durvalumab) to two schedules of radiation therapies (60 Gy in 30 fractions or 60 Gy in 15 fractions) is safe.
Unresectable or inoperable, non-metastatic stage II-III Non-Small Cell Lung Cancer patients who have PD-L1 high expressing tumors (>=50%) within 60 days prior to registration.
24
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.